NanoViricides, Inc. (NYSE American:NNVC) (the Company) reports that clinical trials of its broad-spectrum antiviral drug NV-CoV-2 began on June 17,…
NanoViricides, Inc. (NYSE American:NNVC) (the Company) reports that clinical trials of its broad-spectrum antiviral drug NV-CoV-2 began on June 17,…
NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) a global leader in the development of highly effective antiviral therapies based on a…